Tampa MD's DEA License Revoked for Sharing Prescription Privileges Illegally
Published Date: 4/16/2025
Notice
Summary
Dr. Victor Augusto Silva from Tampa had his DEA registration suspended and then revoked because he let someone else illegally use his license to prescribe drugs. Since he didn’t respond in time to defend himself, the government decided he’s a risk to public safety and took away his registration for good. This means he can’t legally prescribe controlled substances anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — No Prescribing
The Drug Enforcement Administration revoked Victor Augusto Silva, M.D.'s DEA Certificate of Registration No. FS3590266 and denied any other pending registration application in Florida. The Order takes effect May 16, 2025, and means Dr. Silva may not lawfully prescribe controlled substances after that date.
Entrusting DEA Registration Is Strict Liability
The Agency found that allowing an unauthorized person to use a DEA registration to prescribe controlled substances violates federal law (21 CFR 1306.04(a)) and Florida law (Fla. Stat. section 458.331(f)), and that a registrant is strictly liable for misuse. The record states Respondent allowed an unlicensed individual (B.L.) to access and use his registration in 2023, including as recently as December 2023.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
Previous / Next Documents
Previous: 2025-06452 — Ajumobi Agu, M.D.; Decision and Order
Dr. Ajumobi Agu from Las Vegas lost his DEA license because he kept giving out controlled medicines after his state licenses were suspended. Since he didn’t ask for a hearing, the DEA decided to revoke his registration to keep the public safe. This means he can’t legally handle controlled substances anymore, effective immediately, protecting patients and the community.
Next: 2025-06455 — Presidential Declaration Amendment of a Major Disaster for Public Assistance Only for the Commonwealth of Kentucky
Kentucky’s disaster declaration just got an upgrade! This update means more help is coming for public projects damaged by storms, floods, and mudslides starting March 4, 2025. Local governments and public agencies can now access extra support to fix things faster and stronger.